Top Industry Leaders in the Ophthalmic Topical Therapeutics Market
Santen Pharmaceutical Acquired the ophthalmic business of Chemo Unipharm, expanding its portfolio of glaucoma and dry eye treatments.
Sun Pharmaceutical Industries Launched a biosimilar version of Lucentis (ranibizumab) for treating age-related macular degeneration, potentially disrupting the market with a more affordable option.
Novartis Received FDA approval for Vuity (pilocarpine), the first prescription eye drop approved to treat presbyopia, a common age-related vision condition.
Alcon Partnered with Vergence Therapeutics to develop and commercialize gene therapy treatments for eye diseases like Leber's hereditary optic neuropathy.
Akorn Operating Company Launched a generic version of Restasis (cyclosporine), a leading dry eye treatment, offering a more affordable option for patients.
List of Ophthalmic Topical Therapeutics Key companies in the market- Santen pharmaceutical co., Ltd. (Japan)
- Sun Pharmaceutical Industries Ltd (India)
- Novartis AG (Switzerland)
- AbbVie (US)
- Bausch & Lomb Incorporated (US)
- Amneal Pharmaceuticals., LLC (US)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Alcon (Switzerland)
- Akorn Operating Company LLC (US)
- Viatris Inc. (US)